We evaluated Ad-p53 tumor suppressor therapy in a murine tumor model known to be highly resistant to immunotherapy in combination with IL2/IL15 CD122/132 agonists and immune checkpoint blockade. This evidence concerns the gene IL2 and neoplasm.